Navigation Links
Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer
Date:10/2/2007

SANTA FE, N.M., Oct. 2 /PRNewswire-FirstCall/ -- John Cousins, President of Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, testified Monday before the New Mexico State Legislature's Interim Tobacco Settlement Committee in support of the lawmakers' $1.3 million proposal for funding a clinical study using the company's assay for early lung cancer detection.

The New Mexico legislature last year appropriated $350,000 to fund a clinical study that will begin later this year to screen veterans for lung cancer at its earliest stages. If approved, the $1.3 million funding proposal for 2008 would be a continuation of existing funding for the clinical study and will be considered during the state's 30-day legislative session beginning January 15, 2008.

"Members of the Tobacco Settlement Committee are at the forefront of funding essential studies to develop a nationwide screening protocol for lung cancer that ultimately will result in saving millions of lives," said Cousins. "We look forward to being part of this breakthrough effort and we are thrilled to be helping our veterans in this process. The men and women who served our country deserve the very best healthcare. This clinical work will provide just that."

Doug Craft, President of the Black Veterans Association of New Mexico, testified in support of Biomoda's efforts. "We are grateful for this opportunity and plan to work very hard to let our brothers and sisters who served in the military learn about, and be part of, this important opportunity that not only will further essential research, but also save lives."

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins (505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clintons new problem - Is the outgoing American president suffering from skin cancer?
2. Past President Narayanans Condition Still Critical
3. President and Founder of National Obesity Forum Resigns
4. President Bush Urges Citizens to Invest In Health Savings Account (HSAs)
5. President Bush proposes HSAs scheme for the benefit of both the workers and the country
6. President’s verdict: no need to panic over bird fl
7. Delhi Hospitals On Standby For President Bush
8. Former IMO President Shows Interest In Winning General Election
9. Chicken Dishes Were Off The Menu At Pakistan Presidents House
10. Man Appeals to President to Save His Ailing Son
11. President Kalam Meets Striking Medicos However Stir to Continue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: